Radiolabeled Metaiodobenzylguanidine (Mibg) in Diagnosis and Therapy of Neuroblastoma - Results From Basic Research (Review)

Bruchelt, Gernot; Klingebiel, Thomas; Treuner, J.; Beck, Julia; Lode, H; Seitz, Gerhard; Niethammer, D

doi:10.3892/ijo.6.3.705

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most significant observation from the current study is that Another variable to be considered is differences in the noradrenaline transporter (NAT), which is responsible for the saturable, specific uptake of MIBG in neuroblastomas (Bruchelt et al, 1995). The expression of this transporter in neuroblastoma may be regulated by many factors which can act differently in different cell lines.…”

Section: Discussionmentioning

confidence: 91%

“…The expression of this transporter in neuroblastoma may be regulated by many factors which can act differently in different cell lines. An inverse correlation between the expression of NAT and tyrosine hydroxylase, the key regulatory enzyme of the catecholamine synthesis, has Specific activity effect on MIBG uptake G Vaidyanathan et al 1176 been observed for SK-N-SH cells (Bruchelt et al, 1995). It may be possible that the expression of NAT gene is diminished for SK-N-SH cells when implanted in vivo.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity

Vaidyanathan

Friedman²,

Keir³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary The biodistribution of no-carrier-added (n.c.a) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH human neuroblastoma xenografts. No advantage in tumour uptake was observed for the n.c.a. preparation. BALB/c nu/nu mice exhibited lower uptake in highly innervated normal tissues (heart and adrenals) than normal BALB/c mice. In another experiment, the distribution of n.c.a.[131I]MIBG in the absence or presence (3 -9 jg) of MIBG carrier was determined. At both 4 h and 24 h, the heart uptake was reduced by a factor of 1.5 even at a dose of 3 mg MIBG. Tumour uptake was not significantly altered by various amounts of unlabelled MIBG at either time point.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity

Vaidyanathan

Friedman²,

Keir³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The radiopharmaceutical metaiodobenzylguanidine (MIBG) was created in 1979 [52]. 131I-MIBG was used to treat malignant, non resectable or metastatic PCC.…”

Section: High Cellularitymentioning

confidence: 99%

A case of malignant pheochromocytoma of the adrenal gland in a young female

Reddy¹,

Hussain²,

Vasanth³

et al. 2021

ann urol oncol

View full text Add to dashboard Cite

Background Pheochromocytoma is a tumour of the adrenal medulla, derived from catecholamine producing chromaffin cells. Malignant pheochromocytomas constitute 10–25% of all cases. These are difficult to diagnose microscopically. Therefore, malignant pheochromocytomas are diagnosed by the presence of local invasion or metastatic disease. Case presentation We present a case of malignant Pheochromocytoma in a 20-year-old woman from south India with classic symptoms whose urinary metanephrines levels were elevated. After controlling the blood pressure preoperatively and laparoscopic right-sided adrenalectomy was performed. The Postoperative period was uneventful. Histopathology proved to be malignant pheochromocytoma with a PASS score of 16/20 and immunohistochemical staining was positive. DOTATATE PET/CT showed no evidence of disease anywhere else in the body. Conclusion Malignant pheochromocytomas are rare tumor, so they pose a significant diagnostic and therapeutic challenge. Surgery is the mainstay of treatment. DOTATATE PET/CT helps in the localization of metastatic disease.

show abstract

“…The radiopharmaceutical metaiodobenzylguanidine (MIBG) was created in 1979 ( 78 ). MIBG is labeled with 131 I at the meta-position and is taken up by the noradrenaline transporter.…”

Section: Novel Therapies For Mppg According To Their Effects On One Omentioning

confidence: 99%

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer

Jiménez

2018

Front. Endocrinol.

View full text Add to dashboard Cite

Malignant pheochromocytomas and paragangliomas affect a very small percentage of the general population. A substantial number of these patients have a hereditary predisposition for the disease and consequently, bear the risk of developing these tumors throughout their entire lives. It is, however, unclear why some patients with no hereditary predisposition develop these tumors, which frequently share a similar molecular phenotype with their hereditary counterparts. Both hereditary and sporadic tumors usually appear at an early age, and affected people often die before reaching their expected lifespans. Unfortunately, there is currently no systemic therapy approved for patients with this orphan disease. Therefore, pheochromocytomas and paragangliomas are very challenging malignancies. The recognition of genetic and molecular abnormalities responsible for the development of these tumors as well as the identification of effective therapies for other malignancies that share a similar pathogenesis is leading to the development of exciting clinical trials. Tyrosine kinase inhibitors, radiopharmaceutical agents, and immunotherapy are currently under evaluation in prospective clinical trials. A phase 2 clinical trial of the highly specific metaiodobenzylguanidine, iobenguane 131I, has provided impressive results; this radiopharmaceutical agent may become the first approved systemic therapy for patients with malignant pheochromocytoma and paraganglioma by the United States Food and Drug Administration. Nevertheless, systemic therapies are still not able to cure the disease. This review will discuss the development of systemic therapeutic approaches using the hallmarks of cancer as a framework. This approach will help the reader to understand where research efforts currently stand and what the future for this difficult field may be.

show abstract

Radiolabeled Metaiodobenzylguanidine (Mibg) in Diagnosis and Therapy of Neuroblastoma - Results From Basic Research (Review)

Cited by 4 publications

References 0 publications

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity

A case of malignant pheochromocytoma of the adrenal gland in a young female

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer

Contact Info

Product

Resources

About